Bailie G R, Rasmussen R, Eisele G, Luscombe D K
Department of Pharmacy Practice, Albany College of Pharmacy, New York.
Ren Fail. 1993;15(2):225-30. doi: 10.3109/08860229309046156.
We report experience with O-set and UVXD systems. Sixty-nine O-set patients (34 male; mean age +/- SD = 45.7 +/- 13.2 years) were compared with 54 UVXD patients (27 male; 56.8 +/- 16.8 years). Total (mean +/- SD) experience were 974 (14.1 +/- 10.8) months on O-set and 1010.9 (18.7 +/- 15.7) months on UVXD. Thirty-two O-set patients avoided peritonitis; 37 had 91 episodes. Seventeen UVXD patients avoided peritonitis; 37 had 137 episodes. Peritonitis occurred each 10.7 months (O-set) versus 7.4 months (UVXD), which was significantly different (p = 0.032, Z test; 95% confidence interval = -0.142 to +0.226). There were 18 relapses in 9 O-set patients, 34 in 12 UVXD. Gram-positive organisms caused 58.2% and 66%; gram-negative, 13.2% and 8.8%; and culture negative, 24.2% and 23.4% of peritonitis in O-set and UVXD, respectively. The time to first peritonitis was not different, 7.4 +/- 6.6 months O-set and 7.2 +/- 7.9 months (UVXD). There was no difference in the peritonitis-free period, 13.0 +/- 10.0 months (O-set) and 16.5 +/- 14.3 months (UVXD). There were 1.12 (O-set) and 16.1 (UVXD) cases per patient year, and 10.7 (O-set) and 7.43 (UVXD) patient months per episode. The peritonitis rate odds ratio was 1:1.85 (O-set:UVXD).
我们报告了使用O-set和UVXD系统的经验。将69例O-set患者（34例男性；平均年龄±标准差=45.7±13.2岁）与54例UVXD患者（27例男性；56.8±16.8岁）进行比较。O-set的总（平均±标准差）经验为974（14.1±10.8）个月，UVXD为1010.9（18.7±15.7）个月。32例O-set患者未发生腹膜炎；37例发生了91次发作。17例UVXD患者未发生腹膜炎；37例发生了137次发作。腹膜炎发生的间隔时间为每10.7个月（O-set）对比7.4个月（UVXD），差异有统计学意义（p = 0.032，Z检验；95%置信区间=-0.142至+0.226）。9例O-set患者中有18次复发，12例UVXD患者中有34次复发。革兰氏阳性菌分别导致O-set和UVXD中58.2%和66%的腹膜炎；革兰氏阴性菌分别导致13.2%和8.8%；培养阴性分别导致24.2%和23.4%。首次发生腹膜炎的时间无差异，O-set为7.4±6.6个月，UVXD为7.2±7.9个月。无腹膜炎期无差异，O-set为13.0±10.0个月，UVXD为16.5±14.3个月。每年每位患者的病例数分别为1.12（O-set）和16.1（UVXD），每次发作的患者月数分别为10.7（O-set）和7.43（UVXD）。腹膜炎发生率的比值比为1:1.85（O-set:UVXD）。
